Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (NYSE: COO) delivers essential updates from the forefront of medical device innovation through its CooperVision and CooperSurgical divisions. This hub provides investors and healthcare professionals with direct access to official announcements, including product developments, regulatory milestones, and strategic initiatives shaping the vision care and women's health sectors.
Find curated press releases covering earnings results, clinical trial updates, and market expansion activities. Track innovations in silicone hydrogel contact lenses and fertility treatment technologies alongside analysis of industry trends impacting COO's global operations. Our repository simplifies monitoring of key developments across 130+ countries where Cooper's life-enhancing devices serve patients and providers.
Bookmark this page for real-time updates on FDA clearances, acquisition activity, and leadership changes. Subscribe to alerts for breaking news about COO's specialty lens portfolio and reproductive health solutions maintaining its position as a medical technology leader.
CooperCompanies (NYSE: COO) has announced its acquisition of Generate Life Sciences for approximately $1.6 billion. This strategic acquisition enhances CooperSurgical’s portfolio in fertility and newborn stem cell services, enabling better support for fertility clinics and Ob/Gyns. Generate Life Sciences, which reported $250 million in revenues over the last year, is projected to contribute $0.30 to Cooper’s non-GAAP earnings per share in the first year post-acquisition. The deal is set to close in early 2022, pending regulatory approval.
CooperCompanies (NYSE: COO) announced it will release its fourth quarter and full year 2021 financial results on December 2, 2021, at 4:15 PM ET. A conference call to discuss the results will follow at 5:00 PM ET. Interested parties can join by dialing 855-643-4430 (U.S.) or 707-294-1332 (International), using the passcode 'Cooper'. The call will be streamed live via the Investor Relations section of the CooperCompanies website and recorded for later access.
CooperVision, based in San Ramon, Calif., launched a new initiative called "Take Control: Myopia & You" aimed at raising awareness about childhood myopia. This initiative is a response to rising cases of myopia, potentially worsened by increased screen time during the COVID-19 pandemic. The campaign emphasizes the efficacy of MiSight® 1 day contact lenses, which significantly slow myopia progression in children aged 8-12. Spokespersons include young actor Alan Kim and actress Madison Reyes, promoting the program's benefits through direct personal experiences.
CooperCompanies (NYSE: COO) reported a strong fiscal Q3 2021, with revenues increasing by 32% year-over-year to $763.4 million. CooperVision's revenue grew by 24% to $557.5 million, while CooperSurgical saw a remarkable 60% increase to $205.9 million. GAAP diluted earnings per share reached $12.37, a substantial rise from $11.25 in Q3 2020. The company highlighted record performances in both segments, driven by product success and robust cash flow. The fiscal year 2021 guidance has been updated, projecting total revenues of $2.893 to $2.923 billion, reflecting continued growth potential.
CooperVision Canada announces a new campaign featuring pop singer Mitsou Gélinas to raise awareness about children's myopia. The initiative aims to educate parents in Québec on the increase in near vision activities among children, especially post-pandemic, where 59% of parents reported more screen time. The campaign will include advertising and social media collaboration, emphasizing the significance of eye exams before school starts. CooperVision's Brilliant Futures™ Myopia Management Program and its MiSight® 1 day contact lenses are highlighted as effective solutions for managing myopia in children.
CooperCompanies (NYSE: COO) will participate in the Virtual Wells Fargo Healthcare Conference on September 10, 2021, at 1:20 PM ET. Al White, President and CEO, will represent the company in a virtual session. A live webcast can be accessed via the Investor Relations section of CooperCompanies’ website, with a replay available 48 hours post-event. Cooper operates globally with two main divisions: CooperVision, focusing on vision care products, and CooperSurgical, dedicated to women's health. The company is headquartered in San Ramon, CA, employing over 12,000 individuals.
CooperCompanies (NYSE: COO) has received approval from the Chinese National Medical Products Administration (NMPA) for its MiSight® 1 day contact lenses. This innovative lens targets the growing issue of myopia in children aged 8-12, potentially slowing axial length progression. With an estimated 80% prevalence of myopia among high school students in China, this approval positions Cooper to collaborate with eye-care professionals effectively. The company plans to share more details in its earnings call on September 2, 2021.
CooperCompanies (NYSE: COO) will release its third quarter 2021 financial results on September 2, 2021, at 4:15 PM ET. A conference call to discuss the results will follow at 5:00 PM ET, with the live dial-in available for U.S. listeners at 855-643-4430 and international listeners at 707-294-1332. The call will also be accessible via a webcast on the company's website. A recording of the call will be available from 8:00 PM ET on September 2 to September 9, 2021.
CooperCompanies (NYSE: COO) declared a semi-annual dividend of 3 cents per share, set for payment on August 11, 2021. Stockholders of record must hold shares by July 27, 2021. This decision aligns with the board's approved plan for annual dividends, reflecting the company’s commitment to returning value to shareholders. CooperCompanies operates through CooperVision and CooperSurgical, focusing on innovative medical devices.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
